ANGIODYNAMICS INC
ANGONASDAQTrading Snapshot
- Day Range
- $15.44 β $15.74
- 52-Week Range
- $9.39 β $16.29
- Volume
- $2.73B
- Avg Volume
- $2.23B
- Shares Outstanding
- 41.3M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $320M
- Last Q Revenue
- $87M
- P/E Ratio
- -17.7
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-0.88
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.3%
Why Investors Own ANGO
- βHigh-growth profile β revenue up +59.2% YoY with expanding US Equity exposure.
- βHealthy economics β 33% gross margin and 13% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ANGIODYNAMICS INC
ANGOAbout ANGIODYNAMICS INC
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving pati

32,900 Shares in AngioDynamics, Inc. $ANGO Acquired by Canada Pension Plan Investment Board
Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with the Securities and E

AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.